A 79-year-old man visited neurology clinic due to gait ataxia and vertigo for 10 months. Neurologic examination revealed saccadic pursuit, mild dysmetria, impaired tandem gait, and areflexia that recovers after exercise. The amplitude of compound muscle action potentials recorded on the abductor digiti minimi increased up to 6,639.4% during repetitive nerve stimulation at 50 Hz stimulation. This case demonstrates that clinicians should consider Lambert-Eaton myasthenic syndrome as a differential diagnosis when a patient complains of gait ataxia and vertigo.

A 79-year-old man visited neurology clinic due to gait ataxia and vertigo for 10 months. Neurologic examination revealed saccadic pursuit, mild dysmetria, impaired tandem gait, and areflexia that recovers after exercise. The amplitude of compound muscle action potentials recorded on the abductor digiti minimi increased up to 6,639.4% during repetitive nerve stimulation at 50 Hz stimulation. This case demonstrates that clinicians should consider Lambert-Eaton myasthenic syndrome as a differential diagnosis when a patient complains of gait ataxia and vertigo.

A 45-year-old woman with a history of migraine experienced thunderclap headaches, after which cerebral vasospasm was confirmed by brain magnetic resonance angiography. Nimodipine treatment initially improved the headache, but moderate daily headaches persisted despite vasospasm resolution. Conventional headache medications including topiramate, propranolol and amitriptyline proved ineffective. Treatment with fremanezumab, a calcitonin gene-related peptide (CGRP)-targeted therapy, resulted in significant reduction of headache frequency and intensity after 3 months. This case suggests the potential effectiveness of CGRP inhibition for persistent headaches following reversible cerebral vasoconstriction syndrome.

A 45-year-old woman with a history of migraine experienced thunderclap headaches, after which cerebral vasospasm was confirmed by brain magnetic resonance angiography. Nimodipine treatment initially improved the headache, but moderate daily headaches persisted despite vasospasm resolution. Conventional headache medications including topiramate, propranolol and amitriptyline proved ineffective. Treatment with fremanezumab, a calcitonin gene-related peptide (CGRP)-targeted therapy, resulted in significant reduction of headache frequency and intensity after 3 months. This case suggests the potential effectiveness of CGRP inhibition for persistent headaches following reversible cerebral vasoconstriction syndrome.

A 45-year-old woman with a history of migraine experienced thunderclap headaches, after which cerebral vasospasm was confirmed by brain magnetic resonance angiography. Nimodipine treatment initially improved the headache, but moderate daily headaches persisted despite vasospasm resolution. Conventional headache medications including topiramate, propranolol and amitriptyline proved ineffective. Treatment with fremanezumab, a calcitonin gene-related peptide (CGRP)-targeted therapy, resulted in significant reduction of headache frequency and intensity after 3 months. This case suggests the potential effectiveness of CGRP inhibition for persistent headaches following reversible cerebral vasoconstriction syndrome.

No abstract available.
Parkinsonian Disorders*